title: Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A.
abstract: Toll-like receptor (TLR) triggering is an important step in the induction of T helper (Th) type 1 T cells which are key players in protection against the intracellular pathogen Mycobacterium (M.) tuberculosis. Here we report on the construction of a fusion protein consisting of a tuberculosis vaccine candidate mycolyl-transferase antigen 85A (Ag85A, Rv3804c) coupled to the outer membrane lipoprotein I (OprI) from Pseudomonas (P.) aeruginosa, a documented TLR2/TLR4 trigger. Subcutaneous boosting with this fusion protein in the absence of adjuvant increased significantly the Ag85A-specific humoral but not cellular immune responses of Ag85A-DNA vaccinated mice. Intranasal priming of C57BL/6 mice with live, attenuated Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine, followed by intranasal boosting with OprI-Ag85A increased systemic and local antigen-specific interferon (IFN)-gamma and interleukin (IL)-2 responses in spleen, draining cervical and mediastinal lymph nodes and particularly in lung tissue, as compared to responses in mice only vaccinated with BCG vaccine. Despite enhanced immune responses, boosting with OprI-Ag85A did not increase protective efficacy against M. tuberculosis of either plasmid DNA or BCG vaccine in this experimental setting.
authors.affiliation: Mycobacterial Immunology, WIV-Pasteur Institute Brussels, Engelandstraat 642, B1180 Brussels, Belgium.
authors.forename: Tatiana
authors.initials: T
authors.lastname: Gartner
authors.forename: Martijn
authors.initials: M
authors.lastname: Baeten
authors.forename: Samuel
authors.initials: S
authors.lastname: Otieno
authors.forename: Hilde
authors.initials: H
authors.lastname: Revets
authors.forename: Patrick
authors.initials: P
authors.lastname: De Baetselier
authors.forename: Kris
authors.initials: K
authors.lastname: Huygen
mesh_terms: D000217:Acyltransferases / Q000235:genetics / Q000276:immunology*; D000281:Administration, Intranasal; D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology*; D001500:BCG Vaccine / Q000276:immunology; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology*; D007117:Immunization, Secondary; D016753:Interleukin-10 / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D008074:Lipoproteins / Q000235:genetics / Q000276:immunology*; D051379:Mice; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D051193:Toll-Like Receptors / Q000276:immunology*; D014376:Tuberculosis / Q000276:immunology / Q000517:prevention & control*; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000942:Antigens, Bacterial; D001500:BCG Vaccine; D001426:Bacterial Proteins; D008074:Lipoproteins; D011993:Recombinant Fusion Proteins; D051193:Toll-Like Receptors; D019444:Vaccines, DNA; C060507:outer membrane lipoprotein I, Bacteria; D016753:Interleukin-10; D015847:Interleukin-4; D000217:Acyltransferases; C112580:antigen 85A, Mycobacterium tuberculosis